Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

24.39
-0.0600-0.25%
Pre-market: 24.390.00000.00%05:55 EDT
Volume:1.70M
Turnover:41.61M
Market Cap:2.52B
PE:-29.12
High:24.98
Open:24.24
Low:23.96
Close:24.45
52wk High:38.26
52wk Low:20.23
Shares:103.29M
Float Shares:91.60M
Volume Ratio:1.06
T/O Rate:1.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8376
EPS(LYR):-0.8100
ROE:-8.18%
ROA:-17.01%
PB:2.36
PE(LYR):-30.11

Loading ...

Beam Therapeutics shareholders elect Class III directors at annual meeting

Reuters
·
Jun 09

Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity

TIPRANKS
·
May 21

Beam Therapeutics presents Phase 1/2 data for BEAM-302

TIPRANKS
·
May 19

Beam Therapeutics presents Phase 1/2 BEAM-302 AATD trial data at ATS 2026

Reuters
·
May 19

Analysts Conflicted on These Healthcare Names: Omnicell (OMCL), Beam Therapeutics (BEAM) and Zentalis Pharmaceuticals (ZNTL)

TIPRANKS
·
May 13

Beam Therapeutics to present updated BEACON trial biomarker data for risto-cel in SCD at EHA2026

Reuters
·
May 12

Will Beam Therapeutics' (BEAM) Revenue Surge, Pipeline Updates and Added Liquidity Change Its Narrative?

Simply Wall St.
·
May 11

Evercore ISI Sticks to Their Buy Rating for Beam Therapeutics (BEAM)

TIPRANKS
·
May 09

Beam Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 07

Beam Therapeutics Q1 net loss narrows beating analyst estimates

Reuters
·
May 07

Beam Q1 FY26 net loss narrows 12.94% to $94.3 million

Reuters
·
May 07

Beam Therapeutics Q1 Operating Expenses USD 138.953 Million

THOMSON REUTERS
·
May 07

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

GlobeNewswire
·
May 07

A Look At Beam Therapeutics (BEAM) Valuation After TIME Recognition And BEACON Trial Progress

Simply Wall St.
·
May 03

Beam Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 18

JonesTrading Sticks to Its Buy Rating for Beam Therapeutics (BEAM)

TIPRANKS
·
Apr 07

Why Beam Therapeutics (BEAM) Is Up 12.6% After NEJM Base-Editing Sickle Cell Data Publication

Simply Wall St.
·
Apr 06